Aniling – accelerating epigenomics

Company. We are committed to bring advances in the Genomics arena to everyday’s health care and disease prevention.

Technology. Our technology solves DNA sequencing critical limitations allowing simultaneous genome and epigenome analysis.

Products: Aniling products are based on GEUS technology and provide a bolt-on workflow from library preparation to clinical report.

About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.

GEUS-CLL

The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

News

Aniling at ESHG 2026 | Illumina Corporate Session

We are pleased to announce that Aniling will be presenting at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden, as part of the Illumina corporate session. Our colleague …

News

Strategic Collaboration using Illumina sequencing platforms to advance Unified Genomic and Epigenetic Assays in Oncology

Aniling has entered into a strategic collaboration with Illumina where Aniling will integrate its GEUS technology with Illumina sequencing platforms. The collaboration will enable Aniling to access Illumina sequencing platforms to advance its unified genomic and epigenetic …

Read Our Blog

for precision medicine | against cancer | technology innovation